I. Laboratory data of 24-year-old woman referred for assessment of chronic liver disease. DHEAS = Dehydroepiandrosterone sulphate; SHBG = sex hormone binding globulin. Reference ranges are given in parentheses stable over a 15 month period. As a result of the low platelet count and prolonged prothrombin time a follow-up liver biopsy was not performed but circumstantial clinical evidence and investigations including a typical isotope liver scan appearance strongly suggested progression to cirrhosis. Grade 2 oesophageal varices were found at endoscopy.
In view of the severity of the symptoms and evident activity of the liver disease immunosuppressive therapy was commenced with prednisolone 60 mg per day and azathioprine 100 mg per day. In addition, as prophylaxis against secondary variceal haemorrhage, propranolol was commenced in a dose of 20 rng three times per day which reduced the resting pulse rate by 251170. On several occasions during the subsequent weeks the patient described A 24-year-old caucasian woman was referred for assessment of chronic liver disease. At age 21 a diagnosis of classical type 1 autoimmune chronic active hepatitis had been confirmed by the presence of high titres of antinuclear factor (1 : 1248), elevated serum immunoglobulin (lgG 38 giL) and typical appearance on liver biopsy of piecemeal necrosis.
She had a normal menarche at age 14 years but developed secondary amenorrhoea at age 17 with no evidence of cyclical premenstrual symptoms. There was no family history of chronic liver disease or diabetes mellitus. The patient consumed less than 10 units of alcohol per week. She remained well without treatment until age 21 when she developed progressive jaundice, intermittent ascites and experienced an upper gastrointestinal haemorrhage.
Clinical examination revealed stigmata of chronic liver disease, splenomegaly and ascites but with no evidence of portal systemic encephalopathy. Ultrasound scan of the abdomen confirmed these findings and also demonstrated polycystic ovaries with increased stromal echogenicity and multiple small peripheral cysts. The patient had moderate facial acne but was not hirsute or virilized.
Investigations indicated evidence of active hepatitis with impaired hepatic synthetic capacity and severe hyperandrogenaemia as shown in on propranolol, glucose tolerance was normal up to 150 min followed by a period of reactive hypoglycaemia. During the hypoglycaemia phase the patient was symptomatic and the lowest glucose achieved was 1·4 mmollL. The fasting blood glucose was normal at 3·5 mmollL with a fasting serum insulin of 156 pmollL (reference range 13-65 pmollL) indicating significant insulin resistance. The insulin response to the glucose load during the first 150 min was elevated at 5560 pmol/L (520-1560). On cessation of propranolol treatment glucose tolerance was normal up to 150min and there was no subsequent episode of hypoglycaemia.
Fasting blood glucose was now 3·6 mmollL with a serum insulin of 45 pmol/L. The insulin response to the glucose load during the first 150 min was now 1290pmol/L, indicating abolition of the insulin resistance. Withdrawal of therapy was associated with complete remission of symptoms associated with hypoglycaemia.
DISCUSSION
Whilst hypoglycaemia is an acknowledged complication of fulminant liver failure and ethanol consumption, the development of insulin resistance, glucose intolerance and frank diabetes mellitus are more typically recognized in patients with cirrhosis.i-'
Insulin resistance is also a well-documented feature in some patients with polycystic ovary syndrome." The hyperandrogenaemia in our patient although compatible with severe polycystic ovary syndrome is high enough to raise the possibility of an androgen secreting tumour of the ovary or adrenal. This seems unlikely in view of its failure to progress in the period the patient was under review. The hyperandrogenaemia pre-dated the introduction of propranolol. As insulin resistance returned to normal on withdrawal of the drug it was unlikely to be the cause of, or associated with the hyperandrogenaemia in our patient. We are at present unaware of any reports of hyperandrogenaemia or polycystic ovaries in young women with cirrhosis.
The use of beta blockers for the primary and secondary prevention of oesophageal varices is now accepted practice.! These drugs have been implicated as a cause of hypoglycaemia in diabetics and non diabetics in an increasing number of cases since first reported in 1966. 6 ,7 Insulin resistance is a recognized feature of beta-blocker drug therapy and results in an exaggerated episodes of impaired conscious level, dizziness, sweating, slurred speech and headache. After she was admitted to hospital for observation one such attack was witnessed during which the patient claimed to feel 'drunk' a blood glucose was measured at 1. 1 mmollL. During her admission to hospital the patient had no access to alcohol. A prolonged (6 h) oral glucose tolerance test (75 g) was carried out and blood was taken every 30 min for measurement of glucose and insulin. Serum insulin was measured by a double antibody radioimmunoassay.' This was repeated after discontinuation of the propranolol for three weeks. The results are shown in Fig. 1 release of insulin in response to a given glucose load." Both of these findings were evident in our patient and indicate that she retained a good functional mass of pancreatic beta cells. The other hormones important in the counter regulation of glucose are glucagon, adrenaline, growth hormone and cortisol. All are secreted in response to a falling plasma glucose within the physiological range 9 , 10 and also to absolute hypoglycaemia.!' Adrenaline and glucagon are predominantly under the control of beta adrenergic mechanisms and act within minutes to raise the blood glucose. The hyperglycaemic effect of growth hormone and cortisol do not appear for a number of hours and their release is unlikely to be important in rapid glucose regulation. 12 Propranolol compromised the short-term regulation of blood glucose in our patient with resultant hypoglycaemia. It is possible that reduced effective hepatic functional cell mass with impaired metabolism of drugs resulted in an increased concentration of unmetabolized propranolol in the blood. This may have reduced the beta adrenergic stimulation of adrenaline and impaired hepatic glycogenolysis and gluconeogenesis in the face of a falling blood glucose.
The role of beta blockers in the splanchnic haemodynamic response to hypo glycaemia may also be important. The normal response is for a sustained rise in splanchnic blood flow which may be of homeostatic importance in providing metabolic fuel for gluconeogenesis.P This splanchnic vasodilatation is impaired by beta blockers possibly mediated through adrenaline or glucagon and this may have contributed to the hypo glycaemia in our patient.
Not all patients taking beta blockers are prone to hypo glycaemia and clearly further studies are required to determine at which site propranolol acts in patients with liver disease. Whilst these studies are awaited and as an increasing number of patients with advanced liver disease receive beta blockers we need to be aware of hypoglycaemia as a possible complication of this treatment.
